Akston's AKS-699 Shows Promising Pruritus Control Over One Year with Less Treatment Need

Akston's Groundbreaking Study on AKS-699 for Canine Allergy Management

In a remarkable advancement for canine healthcare, Akston Biosciences has presented compelling data on its investigational drug, AKS-699, suggesting significant pruritus control for dogs suffering from atopic dermatitis. Revealed at the recent North American Veterinary Dermatology Forum (NAVDF), the study indicates that AKS-699 can sustain over 80% reduction in itching for an entire year, requiring far less frequent treatments than the currently approved therapy, lokivetmab.

Study Overview

The head-to-head study was presented by Andrea Delpero, the Senior Manager of Pharmacology at Akston. It put AKS-699 against lokivetmab, a popular treatment marketed under the name Cytopoint by Zoetis, in managing pruritus triggered by interleukin-31 (IL-31) in canines. The results displayed not only robust control of pruritus over 12 months but also emphasized that Akston's therapy necessitated fewer doses to achieve results similar to lokivetmab, which typically requires monthly injections.

Key Results and Findings

The research confirmed that AKS-699 can elicit a sustained immune response by inducing the production of anti-IL-31 antibodies, initiated via a three-dose regimen followed by a six-month booster shot. This regimen provided substantial itching relief, with the effects lasting beyond 180 days post-booster. The results not only demonstrate durability but also a favorable safety profile, with AKS-699 being well-tolerated throughout the study duration.

Dr. Todd Zion, co-founder and CEO of Akston, pointed out the tangible relief AKS-699 could offer pet owners. He noted that dogs suffering from atopic dermatitis often need regular veterinary visits, which can be both cumbersome and costly.